A treatment that includes (a) prevention, control, and pyrethroids, Discontinuation or pre-use of cytochrome inhibitors managed simultaneously or jointly by cytochrome P450 1A2 (CYP1A2) inhibitors, two (1) cytochrome P450 1A2 (CYP1A2) and (2) another specific cytochrome CYP2D6 from CYP3A4, CYP2C9, CYP2C19, CYP2B6, and / or (b) with preventive measures. Pyridydine was used in patients receiving a highly toxic-1-a2 vacuum cleaner； or (c) a highly toxic-1-a2 inhibitor was used in patients receiving pyridydine for prevention. This is an effective method of pyrethroid in the treatment of pulmonary fibrosisDiabetic retinitis gouty osteomyelitis ulcerative colitisREFERIDO A UN METODO DE TRATAMIENTO CON PIRFENIDONA QUE COMPRENDE: A) EVITAR, CONTRAINDICAR, DISCONTINUAR O USAR CON PRECAUCION LA ADMINISTRACION CONCOMITANTE O LA CO-ADMINISTRACION DE UN INHIBIDOR DE CITOCROMO P450 1A2 (CYP1A2) QUE ES UN INHIBIDOR MODERADO A FUERTE DE AMBOS (i) CITOCROMO P450 1A2 (CYP1A2) Y (ii) OTRA ENZIMA CYP SELECCIONADA DEL GRUPO QUE CONSISTE DE CYP3A4, CYP2C9, CYP2C19, CYP2B6 Y/O CYP2D6, O B) USAR CON PRECAUCION LA PIRFENIDONA EN PACIENTES QUE RECIBEN UN INHIIDOR FUERTE DE CYP1A2 O C) USAR CON PRECAUCION DE UN INHIBIDOR FUERTE DE CYP1A2 EN PACIENTES QUE RECIBEN PIRFENIDONA. DICHO METODO DE TRATAMIENTO CON PIRFENIDONA ES UTIL PARA EL TRATAMIENTO DE FIBROSIS PULMONAR, RETINOPATIA DIABETICA, GOTA, OSTEOARTRITIS, COLITIS ULCEROSA
